Abstract
The REDUCE-IT trial demonstrated that icosapent ethyl (IPE), a highly purified eicosapentaenoic acid ethyl ester, lowers cardiovascular (CV) events and CV death in statin-treated individuals with mild-moderate hypertriglyceridemia, relatively well-controlled low-density lipoprotein cholesterol (LDL-C) levels and with either known CV disease or diabetes with other risk factors. Inasmuch as over 90% of the REDUCE-IT cohort were White, the generalization of its results to non-White populations is unclear.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.